Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein apheresis in the era of new lipid-lowering therapies.

European heart journal·2026
Same author

Treatment of Clinically Diagnosed Alzheimer's Disease by External Counterpulsation A Randomized Clinical Trial.

American journal of Alzheimer's disease and other dementias·2026
Same author

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

European journal of preventive cardiology·2026
Same author

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.

Atherosclerosis·2026
Same author

A Personalized Medicine Approach is Best for Patients with Homozygous Familial Hypercholesterolemia.

Medical research archives·2025
Same author

Pelacarsen: Mechanism of action and Lp(a)-lowering effect.

Journal of clinical lipidology·2025
Same journal

The Heart-Brain Connection.

Cardiology clinics·2026
Same journal

Overcoming Psychological Barriers to Treatment Adherence: The Case of Antihypertensive Medication.

Cardiology clinics·2026
Same journal

Cardio-oncology Rehabilitation and Mental Health: Current Evidence and Future Perspectives.

Cardiology clinics·2026
Same journal

Cardiac Rehabilitation and Mental Health.

Cardiology clinics·2026
Same journal

Best-Practice Mental Health Interventions Following Acute Cardiovascular Events.

Cardiology clinics·2026
Same journal

Positive Psychology Interventions and Cardiovascular Health: Frequency and Duration to Sustain Cardiovascular Benefits.

Cardiology clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 13, 2026

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

9.4K

Lipoprotein apheresis.

Patrick M Moriarty1, Linda Hemphill2

  • 1Division of Clinical Pharmacology and Atherosclerosis/Lipoprotein-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3008, Kansas City, KS 66160, USA.

Cardiology Clinics
|May 6, 2015
PubMed
Summary
This summary is machine-generated.

Lipoprotein apheresis (LA) effectively lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular events in familial hypercholesterolemia (FH) patients. This therapy also decreases Lp(a) levels, inflammatory markers, and blood viscosity.

Keywords:
AtherosclerosisCVDFamilial hypercholesterolemiaLDL-CLipoprotein apheresisLp(a)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.8K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.9K

Related Experiment Videos

Last Updated: Apr 13, 2026

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

9.4K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.8K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.9K

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Medical Technology

Background:

  • Familial hypercholesterolemia (FH) accelerates atherosclerosis and cardiovascular disease (CVD).
  • Standard lipid-lowering drugs may not sufficiently reduce elevated low-density lipoprotein cholesterol (LDL-C).
  • Lipoprotein apheresis (LA) is an extracorporeal therapy for managing severe hypercholesterolemia.

Purpose of the Study:

  • To evaluate the clinical efficacy of Lipoprotein apheresis (LA) in patients with familial hypercholesterolemia (FH).
  • To assess the impact of LA on cardiovascular disease (CVD) events and key lipid parameters.

Main Methods:

  • Lipoprotein apheresis (LA) therapy was administered to patients diagnosed with FH.
  • Treatment outcomes included changes in LDL-C, Lp(a) levels, and incidence of CVD events.

Main Results:

  • LA therapy significantly reduced LDL-C levels by over 60% in FH patients.
  • LA demonstrated a reduction in cardiovascular disease (CVD) events.
  • The therapy also led to decreased levels of Lp(a), inflammatory markers, and blood viscosity.

Conclusions:

  • Lipoprotein apheresis (LA) is a clinically beneficial therapy for managing familial hypercholesterolemia (FH).
  • LA effectively reduces LDL-C and Lp(a) levels, contributing to a decrease in cardiovascular events.
  • LA offers additional benefits by reducing inflammatory markers and improving hemorheological properties.